Cannabinoid-based therapeutics was welcomed news for one biotech junior Thursday. Here’s some small stocks making big moves on Thursday, February 16, 2017 (as of 4 pm EST):
Revive Therapeutics Ltd. (TSXV: RVV) shares climbed 61% to $0.225 on Thursday after the biotech junior announced that it is expanding its product pipeline through the development of cannabinoid-based therapeutics targeting liver diseases.
As well, shares of Primero Mining Corp. (TSX: P) slipped 13% to $1 as the precious metals miner announced that unionized employees at its San Dimas mine in Mexico have initiated a strike action, resulting in the complete stoppage of mining and milling activities at the site.
NexJ Systems Inc. (TSX: NXJ), meanwhile, reported that its fourth-quarter revenue rose 21% to $9.6 million, while swinging to a profit of $1.9 million in the quarter from a net loss of $2.0 million during the same period last year. NexJ Systems stock moved up 17% to $4.39 following the announcement.
Finally, Ivrnet Inc. (TSXV: IVI) shares gained 14% to $0.04 after the software and communications company that provides online management of operations and financial processing for membership driven organizations announced the signing and financing of seven new contracts for its Ivrnet Central membership management software.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Revive Therapeutics Ltd. (TSXV: RVV) shares climbed 61% to $0.225 on Thursday after the biotech junior announced that it is expanding its product pipeline through the development of cannabinoid-based therapeutics targeting liver diseases.
